Sugi Predict

Sugi Predict / Targets / DDB1

DDB1

DNA damage-binding protein 1 · Q16531 · DDB1 on Sugi Atlas →

154,190 patent compounds predicted against DDB1, 76,653 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Hydrochloric Acid Hydrochloric Acid (SCHEMBL284301) 0.72 20/20
SCHEMBL328540 SCHEMBL328540 0.56 20/20
Avadomide Avadomide (SCHEMBL282749) 1.00 19/20
SCHEMBL459725 SCHEMBL459725 1.00 19/20
SCHEMBL476904 SCHEMBL476904 0.80 19/20
SCHEMBL283241 SCHEMBL283241 0.75 19/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL284302) 0.74 19/20
SCHEMBL476975 SCHEMBL476975 0.73 19/20
SCHEMBL283120 SCHEMBL283120 0.68 19/20
SCHEMBL286218 SCHEMBL286218 0.66 19/20
SCHEMBL283467 SCHEMBL283467 0.59 19/20
SCHEMBL284416 SCHEMBL284416 0.59 19/20
SCHEMBL286219 SCHEMBL286219 0.52 19/20
SCHEMBL476960 SCHEMBL476960 0.81 18/20
SCHEMBL476936 SCHEMBL476936 0.80 18/20
SCHEMBL282492 SCHEMBL282492 0.79 18/20
SCHEMBL283184 SCHEMBL283184 0.79 18/20
SCHEMBL283314 SCHEMBL283314 0.79 18/20
SCHEMBL476922 SCHEMBL476922 0.78 18/20
SCHEMBL476977 SCHEMBL476977 0.72 18/20

Clinical trials — most relevant to DDB1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer. PHASE4RECRUITING
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency PHASE2/PHASE3RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial) PHASE2UNKNOWN
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies PHASE1/PHASE2RECRUITING
Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100 PHASE1/PHASE2COMPLETED
S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer PHASE2COMPLETED
Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer PHASE2UNKNOWN
Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer PHASE2UNKNOWN
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration PHASE2UNKNOWN
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors PHASE1COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers PHASE1COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer PHASE1ACTIVE_NOT_RECRUITING
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Study of the Effect of Innate on the Inflammatory Response to Endotoxin nanRECRUITING
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC nanUNKNOWN
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581 nanCOMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease nanCOMPLETED
Prognostic Biomarkers in Patients With Urothelial Carcinoma nanCOMPLETED
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients nanACTIVE_NOT_RECRUITING
Vascular Senescence and Atherosclerotic Plaque Vulnerability nanRECRUITING
Pesticide Associated Lymphomas: Expression of Treatment Resistance Genes nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a DDB1 binder may also engage these)

ProteinNameSimilarity
Q9ESW0 — 1.000 Q9ESW0 →
A1A4K3 — 1.000 A1A4K3 →
Q805F9 — 1.000 Q805F9 →
Q3U1J4 — 1.000 Q3U1J4 →
Q6P6Z0 — 1.000 Q6P6Z0 →
P33194 — 1.000 P33194 →
Q5R649 — 0.999 Q5R649 →
O49552 — 0.996 O49552 →
Q6E7D1 — 0.996 Q6E7D1 →
Q9XYZ5 — 0.995 Q9XYZ5 →
Q6L4S0 — 0.994 Q6L4S0 →
Q6QNU4 — 0.993 Q6QNU4 →
A0JN52 — 0.992 A0JN52 →
Q5RBI5 — 0.992 Q5RBI5 →
Q921M3 — 0.991 Q921M3 →
Q1LVE8 — 0.991 Q1LVE8 →
P0DKL6 — 0.989 P0DKL6 →
P0DKL4 — 0.989 P0DKL4 →
Q9M0V3 — 0.988 Q9M0V3 →
Q9W0M7 — 0.986 Q9W0M7 →
SF3B3 Splicing factor 3B subunit 3 0.986 landscape →
Q7RYR4 — 0.984 Q7RYR4 →
Q9CWF6 — 0.983 Q9CWF6 →
Q4PGM6 — 0.983 Q4PGM6 →
Q6AX60 — 0.982 Q6AX60 →
Q4WLI5 — 0.982 Q4WLI5 →
Q9UTT2 — 0.981 Q9UTT2 →
P0CR23 — 0.981 P0CR23 →
Q8BU03 — 0.980 Q8BU03 →
Q52E49 — 0.980 Q52E49 →